Mathieu, Chantal <br/><br/>
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.  [electronic resource] 

 -  Diabetes, obesity & metabolism  05 2018 
 - 1148-1155 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.13205  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Blood Glucose--analysis<br/>Blood Glucose Self-Monitoring<br/>Diabetes Mellitus, Type 1--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Compounding<br/>Drug Monitoring<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Follow-Up Studies<br/>Glycated Hemoglobin--analysis<br/>Humans<br/>Hyperglycemia--prevention & control<br/>Hypoglycemia--chemically induced<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin Aspart--administration & dosage<br/>Insulin Detemir--administration & dosage<br/>Male<br/>Meals<br/>Middle Aged